APA (7th ed.) Citation

Chihara, N., Lee, J., Yu, J. C., Numajiri, N., & Misu, T. (2026). Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan. Neurology & Therapy, 15(4), 1539. https://doi.org/10.1007/s40120-026-00938-8

Chicago Style (17th ed.) Citation

Chihara, Norio, Justin Lee, Jeffrey C. Yu, Naoki Numajiri, and Tatsuro Misu. "Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan." Neurology & Therapy 15, no. 4 (2026): 1539. https://doi.org/10.1007/s40120-026-00938-8.

MLA (9th ed.) Citation

Chihara, Norio, et al. "Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan." Neurology & Therapy, vol. 15, no. 4, 2026, p. 1539, https://doi.org/10.1007/s40120-026-00938-8.